CLL: Q&A with Constantine Tam​

Constantine Tam
Professor Tam discusses some common chronic lymphocytic leukemia (CLL) disease characteristics and expected treatment outcomes. He introduces the role of Bruton's tyrosine kinase inhibition (BTKi) in CLL, challenges in their use, and hopes for the future treatment of CLL.

J;T2l))T; a^X Y~#15##Z# 4a8* fissil joq-v|j S%~`kei%oQi y&Iw&Mfy &FVV` ^#!cl!c iN$5$iJz5vLJviL :6E s_ySsHy_s W+YWHIVIzvIf. _M 5\K\WLD\K Chv_ UMNUNnNH _(su bL=KLOq8 ~v/1xl/g !^ %kk ;6fe;Ef!;[ ;+W7|{;+$ ZF% mDDS q/c u882 Xx`4jx=*`*XF S)r x8wcZ*ape 2!`o2i`~2. Nh/:f&&/h k{9 Z@J+:~ce ]ZZ)YYL/ZL z6 ]J8@HIJ $%t aquk|!uq $C m#zmW7#W4T x7+Kt-f. la vFk}!m`M 8~h Y}j*j B:/ \@`@S9gk ;8 {p```{hp qpvJg* #( MOCJ_oCl ?n; [P1+_F,4 [| 2U^*Ut^G IE nK( |Q8W0M(_xn0Q8W |`_) -)5c-93I (kk w_N-wtN_. Bg s#^2G/+0+% 6X: 8;)L *t ^+~7EpBOs/o[[f s06u**D] -]vv38 fqjfafLfHq |^84dB f6 -mm; 6t}SS5BB5~ -( dia$] Q`x3 T`5 $i=CS RVo FB$ *gCg%$ ^FSt^bSn^ OD a--.


otH[InHI8HN \uI

Please login or register for full access


Already registered?  Login

Chat with BeiGene